The development of new vaccines is a long and costly process in which it is often difficult to find funding, due to the uncertainty in the sector. However, it is necessary in order to find solutions to improve our health. This week...
M&A advisors with expertise in the technology sector
funding for biotechnology
Latest Sectoral Reports |
Last Entries
Biotech operations: Minoryx, Suanfarma, Ability Pharma and Oryzon Genomics
According to data provided by Ascri, in the first half of 2015, biotechnology, with 24 transactions, is the sector with the second highest number of transactions. In the last month, we have witnessed several operations for an amount equal to or greater than €10M.